Bristol Pays Tranzyme $10 Million For Collaboration For Discovery Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Tranzyme’s first alliance with a Big Pharma should give it a cushion to advance its own pipeline, which includes two Phase II candidates.
You may also be interested in...
Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug
Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.
Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug
Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.
Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.